Gamma secretase inhibitors

Patent metadata

Field	Value
Publication number	US-9226927-B2
Application number	US-201214342953-A
Country	US
Kind code	B2
Filing date	Sep 4, 2012
Priority date	Sep 9, 2011
Publication date	Jan 5, 2016
Grant date	Jan 5, 2016

Abstract

Disclosed herein are compounds of Formula (I) (I) and pharmaceutically acceptable salts thereof, wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions containing the compound of Formula (I) and use of the compound in the treatment of neurodegenerative diseases or conditions such as Alzheimer's disease.

First claim

What is claimed:

1. A compound of Formula (I)

or a pharmaceutically acceptable salt thereof, wherein
R is selected from the group consisting of:
(1) -pyridinyl,
(2) -pyrazolinyl,
(3) -1,2,4-oxadiazolyl,
(4) -(C1-C2)alkyl-pyridinyl,
(5) -(C1-C2)alkyl-pyrazolinyl, and
(6) -(C1-C2)alkyl-1,2,4-oxadiazolyl,
wherein the pyridinyl, pyrazolinyl, and -1,2,4-oxadiazolyl, is unsubstituted or substited with one L 1 group;
R 1 is independently selected from the group consisting halogen, (C1-C6)alkyl, —CN, —CF 3 , —O—(C1-C6)alkyl, —O-(halo(C1-C6)alkyl), —C(O)—O—(C1-C6)—OH-substituted (C1-C4)alkyl, halo(C1-C6)alkyl, —(C1-C4)alkoxy-OH, —(C1-C4)alkoxy(C1-C4)alkoxy and —S(O) 2 (C1-C6)alkyl;
n is 0, 1, 2, or 3;
Ar is selected from the group consisting of phenyl optionally substituted with 1 or 2 L 2 groups, and pyridyl optionally substituted with 1 or 2 L 2 groups;
L 1 is independently selected from the group consisting of —OCH 3 , —NH 2 , ═O, and (C1-C5)alkyl; and
L 2 is independently selected from the group consisting of halogen, (C1-C6)alkyl , —CN, —CF 3 , —O—(C1-C6)alkyl, —O-(halo(C1-C6)alkyl), —C(O)—O—(C1-C6)alkyl, —OH-substituted(C1-C6)alkyl, halo(C1-C6)alkyl, —OH-substituted (C1-C4)alkoxy, —(C1-C4)alkoxy(C1-C4)alkoxy and —S(O) 2 (C1-C6)alkyl.

2. The compound of claim 1 , wherein n is 2, each R 1 is the same or different halogen, and the R 1 groups are bound to the phenyl moiety as shown in Formula (II):

3. The compound of claim 2 , wherein the halogen is fluoro.

4. The compound of claim 1 , wherein Ar is selected from the group consisting of p-Cl-phenyl-, p-CN-phenyl-, p-CF 3 -phenyl, pyridyl, and pyridyl substituted with 1 or 2 substituents independently selected from the group consisting of halogen, —(C1-C6)alkyl, —CN, —CF 3 , O—(C1-C6)alkyl, —O-halo(C1-C6)alkyl, —C(O)—O—(C1-C6)alkyl, —OH-substituted (C1-C6)alkyl, - -halo(C1-C6)alkyl, -OH substituted (C1-C4)alkoxy and —(C1-C4)alkoxy(C1-C4)alkoxy.

5. The compound of claim 4 , wherein Ar is p-Cl-phenyl.

6. The compound of claim 1 , having the Formula:

7. The compound of claim 6 , wherein Ar is p-Cl-phenyl, n is 2, each R 1 is the same or different halogen, and the R 1 groups are bound to the phenyl moiety as shown in Formula (II):

8. A compound which is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

9. A compound which is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

11. A pharmaceutical composition comprising the compound of claim 8 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutical acceptable carrier.

12. A pharmaceutical composition comprising the compound of claim 9 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutical acceptable carrier.

Assignees

• Wu Wen-Lian
• Burnett Duane A
• Merck Sharp & Dohme

Inventors

• Wu Wen-Lian
• Burnett Duane A

Classifications

• C07D493/04

  Ortho-condensed systems · CPC title

• A61K31/4155

  non condensed and containing further heterocyclic rings · CPC title

• A61K31/4433

  containing a six-membered ring with oxygen as a ring hetero atom · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/497

  containing further heterocyclic rings · CPC title